Name (Synonyms) | Correlation | |
---|---|---|
drug963 | Fondaparinux Wiki | 1.00 |
drug2475 | Test: Favipiravir 200 mg (LOQULAR) Wiki | 1.00 |
drug115 | Acetylsalicylic acid Wiki | 1.00 |
drug2522 | Tirofiban Injection Wiki | 1.00 |
drug588 | Clopidogrel Wiki | 0.71 |
Name (Synonyms) | Correlation | |
---|---|---|
D016769 | Embolism and Thrombosis NIH | 0.58 |
D004617 | Embolism NIH | 0.30 |
D013927 | Thrombosis NIH | 0.23 |
D011024 | Pneumonia, Viral NIH | 0.13 |
D011014 | Pneumonia NIH | 0.06 |
D045169 | Severe Acute Respiratory Syndrome NIH | 0.05 |
D018352 | Coronavirus Infections NIH | 0.04 |
Name (Synonyms) | Correlation | |
---|---|---|
HP:0001907 | Thromboembolism HPO | 0.24 |
HP:0002090 | Pneumonia HPO | 0.06 |
There is one clinical trial.
A single dose of Reference product containing 200 mg favipiravir and a single dose of Test product containing 200 mg favipiravir or vice versa; administered with 240 mL of water at room temperature, in each period under fasting conditions with current pandemic precautions.
Description: AUC0-tlast of favipiravir
Measure: Primary PK End Points AUC0-tlast Time: 12 weeksDescription: Cmax of favipiravir
Measure: Primary PK End Points Cmax Time: 13 weeksDescription: AUC0-inf of favipiravir
Measure: Secondary PK End Points AUC0-inf Time: 14 weeksDescription: tmax of favipiravir
Measure: Secondary PK End Points tmax Time: 15 weeks